Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869075 | 0.83 | AAK1 (0.52) | AAK1CYP17A1CISD2 | |
| SCHEMBL198874 | 0.81 | HDAC1 (0.49) | HDAC1HDAC2HDAC3AAK1CYP17A1 | |
| SCHEMBL29371288 | 0.81 | HDAC1 (0.59) | HDAC1HDAC2HDAC3 | |
| SCHEMBL30474668 | 0.81 | HDAC1 (0.49) | HDAC1HDAC2HDAC3AAK1CYP17A1 | |
| SCHEMBL196444 | 0.81 | HDAC1 (0.59) | HDAC1HDAC2HDAC3 | |
| SCHEMBL25211751 | 0.81 | ABCB1 (0.44) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3410364 | 0.81 | HPGD (0.49) | AAK1CYP17A1CISD2 | |
| SCHEMBL5868898 | 0.81 | HDAC2 (0.50) | HDAC1HDAC2HDAC3AAK1CYP17A1 | |
| SCHEMBL23960904 | 0.81 | AAK1 (0.48) | HDAC1HDAC2HDAC3AAK1CYP17A1 | |
| Ammonia Solution, Strong SCHEMBL21835779 | 0.81 | HDAC1 (0.58) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC2 9/4885HDAC3 8/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC2 8/4885HDAC3 9/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC2 8/4885HDAC3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.